Flecoxin

Quick links to important sections

Flecoxin

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flecoxin

Quick Facts: Flecoxin (Bromhexine)

Property Description
Active ingredient Bromhexine hydrochloride
Form Tablet, Oral Solution, Syrup
Pharmacological class Mucolytic Agent, Expectorant
Common use Relief of productive cough and mucus-related respiratory symptoms
Origin Synthetic organic compound

What is Flecoxin?

Flecoxin is a single-ingredient medicinal preparation primarily used to treat respiratory conditions involving excessive or thick mucus. The drug’s active ingredient is Bromhexine hydrochloride, which is fundamentally classified as a mucolytic agent and expectorant.

What Type of Medicine is Flecoxin and What is it Made Of?

Flecoxin belongs to the secretolytic pharmacological class, meaning its primary action is to reduce the viscosity of secretions and promote their elimination. Its active component, Bromhexine hydrochloride, is a synthetic organic compound conceptually derived from the Adhatoda vasica plant. This compound works by chemically breaking down the complex mucopolysaccharide fibers in the mucus, which leads to a decrease in mucus viscosity.

The medication is specifically indicated as a mucolytic agent for the treatment of respiratory disorders associated with a productive cough. The formulation is specifically a single-ingredient product, which distinguishes it from other brands that may feature Bromhexine in combination with antitussives or decongestants, offering a focused therapeutic effect.

Flecoxin: Available Forms and General Purpose

Flecoxin is generally administered via the oral route of administration and is available in several pharmaceutical preparations, including the solid tablet form, as well as liquid formats such as oral solution and syrup. These different forms target various patient groups, offering flexibility for administration to both adults and children.

By liquefying the mucus and enhancing its movement, Flecoxin supports overall bronchial health and generally helps to relieve the discomfort associated with a congested or productive cough. The general purpose of the medicine is to assist in managing respiratory tract disorders characterized by abnormal mucus secretion and impaired mucus transport.

What side effects are possible with Flecoxin?

Possible side effects and safety information

The safety profile for Flecoxin (Flecainide Acetate) is structured by regulatory bodies to communicate both the most common and the most serious potential adverse reactions. The primary safety concern documented in official labeling is the risk of proarrhythmia, which involves the development of new or worsened cardiac rhythm disturbances, including potentially life-threatening ventricular arrhythmias.

Adverse reactions are classified by frequency as defined in authoritative regulatory documents:

  • Very Common: Effects occurring in more than 1 in 10 individuals, most notably dizziness, light-headedness, and visual disturbances such as blurred vision or difficulty focusing. These effects are often described as usually transient.
  • Common: Effects occurring in up to 1 in 10 individuals, including proarrhythmia, shortness of breath (dyspnoea), fatigue, general lack of energy (asthenia), and swelling (oedema).
  • Uncommon/Rare: Less frequent documented effects involve the gastrointestinal system (e.g., nausea, vomiting, constipation), nervous system (e.g., tremor, syncope, headache), and haematological system (decreases in white blood cell or platelet counts).

Serious Safety Considerations

Official labeling defines significant safety restrictions. The medicine is contraindicated in individuals with certain pre-existing heart conditions, such as second- or third-degree atrioventricular (AV) block or chronic atrial fibrillation (AF) without a pacemaker, and in those with existing or a history of congestive cardiac failure. Furthermore, the official prescribing information includes specific safety guidance for patients with significant renal or hepatic impairment, where slower drug elimination may necessitate careful monitoring of plasma concentrations due to the increased risk of adverse cardiac events.

Overdose and Emergency Response

Flecoxin Overdose and When to Seek Help

Flecoxin (Flecainide) has a narrow therapeutic index, meaning the difference between an effective dose and a dose causing serious toxicity is small. Overdose can lead to life-threatening cardiac and non-cardiac effects. Immediate medical attention is crucial if an overdose is suspected.

Signs and Symptoms of Overdose

Symptoms of Flecoxin overdose are related to its effect as a potent sodium channel blocker, which slows electrical conduction in the heart. Effects can be severe and may progress rapidly:

System Common Symptoms
Cardiovascular Slow, irregular heartbeat (bradycardia), very fast and dangerous heart rhythms (ventricular tachycardia), significantly widened QRS complex on ECG, low blood pressure (hypotension), fainting (syncope), or cardiac arrest.
Non-Cardiac Severe dizziness, visual disturbances, headache, nausea, vomiting, or seizures.

When to Seek Immediate Help

Call emergency services immediately if you or someone else has taken more than the prescribed dose of Flecoxin, or if any of the above serious symptoms occur, regardless of the dose taken. Do not wait for symptoms to worsen. Due to the drug's long half-life, effects can be delayed or prolonged. Medical treatment may include administration of sodium bicarbonate and intensive supportive care.

Therapeutic Uses of Flecoxin

Main Uses of Flecoxin

Flecoxin is a medication primarily classified as an anti-arrhythmic agent. It is used to manage and prevent certain types of serious heart rhythm disorders (arrhythmias). By affecting the electrical signals in the heart, it helps maintain a regular and steady heartbeat.

Primary Conditions Treated

  • Atrial Fibrillation and Flutter: Flecoxin is utilized to prevent the recurrence of paroxysmal atrial fibrillation (PAF) and paroxysmal atrial flutter (PAF) in patients who do not have structural heart disease.
  • Supraventricular Tachycardia (PSVT): It is indicated for the prevention of paroxysmal supraventricular tachycardias, including atrioventricular nodal re-entrant tachycardia and Wolff-Parkinson-White syndrome.
  • Ventricular Arrhythmias: In specific clinical settings, it is used to treat life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia.

Therapeutic Benefits

The primary goal of Flecoxin therapy is the restoration and maintenance of normal sinus rhythm. By stabilizing the heart's electrical activity, the medication can provide several clinical benefits:

  • Reduction of Arrhythmia Episodes: The medication works to decrease the frequency and duration of irregular heartbeat episodes.
  • Symptom Management: Successful management of heart rhythm can lead to a reduction in associated symptoms such as heart palpitations, shortness of breath, and lightheadedness.
  • Improved Quality of Life: By maintaining a steady heart rate, patients may experience an increased ability to engage in daily activities without the disruption caused by sudden rhythm changes.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Flecoxin

The use of Flecoxin (Flecainide Acetate) is strictly defined by official regulatory criteria, primarily related to the patient’s cardiac structure, function, and conduction system integrity. The medicine is contraindicated and must not be used in populations with significant pre-existing heart conditions.

This includes individuals diagnosed with cardiac failure, cardiogenic shock, or any form of structural heart disease, particularly those with low left ventricular function. It is also prohibited for patients with certain electrical disorders, such as second-degree or greater atrioventricular (AV) block or sick sinus syndrome, unless a functioning artificial pacemaker is present.

Restrictions for Special Populations

Population Group Regulatory Status
Children Under 12 Not recommended due to insufficient evidence.
Renal/Hepatic Impairment Restricted use requiring close monitoring and lower initial dosage.
Pregnancy/Lactation Restricted use only if the potential benefit outweighs the documented risks.

Use is not recommended for chronic atrial fibrillation or for asymptomatic ventricular arrhythmias after a myocardial infarction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flecoxin (Flecainide Acetate) has officially documented interaction patterns that are classified based on the resulting pharmacokinetic (PK) and pharmacodynamic (PD) outcomes, as defined in regulatory documents.

Interaction Type Interacting Substance Categories Official Interaction Outcome Description
Metabolic (PK) CYP2D6 Inhibitors (e.g., Amiodarone, Cimetidine, Quinidine) May increase Flecainide plasma concentrations due to inhibition of clearance, potentially two-fold or more in some cases.
Pharmacodynamic (PD) Other Antiarrhythmics, Beta-Blockers Combining with these agents may result in additive negative inotropic effects, officially described as a decrease in myocardial contractility.

Specific Exposure Modification and Environmental Factors

Co-administration with Cimetidine is documented to increase Flecainide plasma levels by approximately 30%. Taking the medication with Digoxin is documented to result in an increase in plasma digoxin levels by 13% to 19%. Substances that alkalinize the urine, such as Acetazolamide, are officially noted to decrease Flecainide renal excretion, thereby increasing systemic exposure. Conversely, tobacco smoking may lead to lower serum Flecainide levels.

Population and Timing Constraints

Regulatory documents note that severe renal impairment or significant hepatic impairment requires caution due to the risk of reduced clearance and increased systemic exposure. When initiating Flecainide after another antiarrhythmic, the label suggests allowing several half-lives of the previous agent to elapse. In infants, the co-administration with milk is noted to decrease Flecainide absorption.

Mechanism of Action

The mechanism of action of Flecoxin, driven by its active ingredient Bromhexine hydrochloride, focuses on modulating the physicochemical properties of respiratory secretions and influencing the body's natural clearance systems. The core effects involve two distinct, yet interconnected, mechanistic domains.


Molecular Action: Liquefaction of Mucus Fibers

Flecoxin exerts its primary mucolytic action by chemically initiating the depolymerization of mucopolysaccharide fibers within the mucus gel layer. It is believed to stimulate the release of certain lysosomal enzymes that catalyze this process. This molecular fragmentation reduces the viscosity and elasticity of the secretions, directly altering the rheology of the mucus.


Systemic Effect: Boosting Mucociliary Transport

The drug's secondary, secretolytic mechanism involves modulating the fluid environment and influencing the transport capacity of the airways. Flecoxin stimulates serous cells in the bronchial glands, increasing the production of watery secretions. This dilutes the mucus and contributes to the establishment of the sol-layer beneath the mucus gel. This, coupled with an enhancement of the ciliary beat frequency, increases the propulsion of the mucus gel layer. This action enhances the mucociliary clearance pathway, supporting the transport of the liquefied material.

Dosage and Administration Information

How to Use Flecoxin (Flecainide Acetate)

Flecoxin, or Flecainide Acetate, is an antiarrhythmic medication whose usage must strictly adhere to established dosing and administration standards.

Official Routes and Administration Schedule

Flecoxin is typically administered via the oral route (tablet or solution) for long-term maintenance therapy, taken generally twice daily (BID). The intravenous (IV) route is reserved for rapid control in acute situations and must be administered slowly over a minimum of 10 minutes in a monitored setting. Oral administration can occur with or without food; however, patients using the oral solution should be mindful that dairy products may interfere with absorption, requiring a time separation from intake.

Standard Dosing and Adjustment Rules

Therapy must begin with a low initial dose (e.g., 50 mg BID for PSVT/PAF or 100 mg BID for sustained VT) and requires gradual titration to reach the effective maintenance level. Dose increases should occur no more frequently than once every four days, as this time interval is necessary to achieve stable drug concentrations in the body. The maximum daily dose permitted for sustained Ventricular Tachycardia is 400 mg/day.

Contextual and Population-Specific Use

Initiation of Flecoxin for specific conditions, such as sustained Ventricular Tachycardia, must be performed in a hospital setting under continuous heart rhythm monitoring. Monitoring of both the heart's electrical activity and drug concentration in the blood (plasma trough levels) is required during the adjustment phase. Dose reduction is indicated for individuals with severe kidney impairment (e.g., maximum initial dose 100 mg/day), and specific dosing regimens based on body surface area are used for the pediatric population.

Recent Clinical Evidence

Flecoxin: Recent Clinical Evidence

This section summarizes the published research and clinical evaluation of Flecoxin (Flecainide Acetate), focusing on the types of studies that research examined, the outcomes they measured, and what remains unclear in the evidence landscape.


Evidence for Restoration and Maintenance of Normal Heart Rhythm (Supraventricular Arrhythmias)

Flecoxin was evaluated in research exploring its use in specific arrhythmias, which are conditions characterized by fluctuating or episodic manifestations of irregular heart rhythms, such as Atrial Fibrillation (AF) and Paroxysmal Supraventricular Tachycardia (PSVT). The core research involved a series of Randomized Controlled Trials (RCTs), which are a central study design in clinical evaluation, alongside several comprehensive Meta-analyses.

Studies monitored patient-reported outcomes describing perceived discomfort and measured rhythm status, including the time to normal rhythm and the duration it was observed in participants. The evidence base includes comparative data related to how symptoms evolved when compared to a placebo.

The results apply only to the populations studied—specifically, adults who did not have significant structural heart disease. Long-term effects are not fully established beyond the intermediate follow-up periods of the core trials.

Evidence for Prevention of Documented Ventricular Arrhythmias

Flecoxin was observed in research exploring its use for certain severe rhythm disturbances like life-threatening Ventricular Tachycardia (VT). This research included a pivotal, large-scale Randomized Controlled Trial (CAST). The studies examined outcomes related to physical discomfort and critical total mortality endpoints.

In this context, the findings were mixed, particularly when the pivotal trial monitored outcomes among individuals who had experienced a prior heart attack. Data show patterns related to severe regulatory restrictions on the studied population for this use. The results apply only to the populations studied and data for certain groups remain insufficient in the core evidence base.

Research Gaps and Areas of Uncertainty

One point of uncertainty remains regarding the highly restrictive nature of the evidence for both main uses. Findings describe group patterns, not personal outcomes. The research does not determine whether an individual will respond similarly, and patterns related to co-existing structural heart disease are not established.

Furthermore, data are still emerging for rare genetic conditions where sample sizes were modest, and subgroup findings are uncertain. Long-term effects are not fully established across all indications, and research is ongoing.

Key Studies & References

  1. Flecainide - StatPearls (NCBI Bookshelf) - Evidence and Outcomes
  2. Label: FLECAINIDE ACETATE tablet - DailyMed (Official Regulatory Monograph)

Frequently Asked Questions (FAQ)

Common questions about Flecoxin (FAQ)

Q: What is Flecoxin used for exactly?

Regulatory documents state that Flecoxin has two distinct sets of indications: it is used for the management of specific heart rhythm disturbances like supraventricular tachycardias, and it is also indicated as a mucolytic agent to help clear thick mucus in respiratory conditions. This dual description reflects the different uses found in official product information.

Q: Does Flecoxin interact with common blood pressure medications?

Official labeling warns that combining Flecoxin with certain types of blood pressure medications, specifically Beta-Blockers, may increase the risk of an additive effect on heart muscle function, which is described as a negative inotropic effect. Other classes of blood pressure medication are not specifically addressed in the same warning category.

Q: Can older adults or the elderly safely use Flecoxin?

Official documents advise that Flecoxin should be used with caution in the elderly population. This is due to the potential for reduced kidney function, which can affect how the body processes the medication. Close monitoring and possible dose adjustments may be required to ensure appropriate use in this group.

Q: Are there any specific dietary restrictions mentioned for people taking Flecoxin?

Official product information states that the oral solution form of Flecoxin may have reduced absorption if taken with dairy products. Separately, substances that make the urine less acidic are noted in regulatory documents to decrease the body's rate of eliminating the drug.

Q: Are there different dose strengths available for Flecoxin?

Yes, Flecoxin is generally supplied in multiple dose strengths for oral tablet forms, such as 50 mg and 100 mg examples provided in official documentation. The medication is also available in liquid forms, including oral solution or syrup, which are available for oral administration.

Q: Does Flecoxin interact with herbal supplements like St. John's Wort?

Regulatory documents indicate that Flecoxin is broken down by a specific enzyme in the body known as CYP2D6. Because some herbal products and supplements can affect this enzyme's activity, combining them with Flecoxin may change the level of drug in the bloodstream.

Q: How long does it usually take before Flecoxin starts to show an effect?

The full therapeutic effect of the drug for cardiac rhythm management often becomes more apparent after several days of regular therapy. This timeframe is related to the four-day interval recommended in official protocols to allow the drug to reach stable concentrations in the body during the adjustment phase.

Q: Do I need to take Flecoxin forever, or is it a short-term treatment?

Official documents describe the use of Flecoxin for heart rhythm management as long-term maintenance therapy. However, when used as a mucolytic, the medication is generally prescribed for acute episodes. The duration of therapy will depend on the treating physician's assessment of the condition.

Q: What is the half-life of Flecoxin?

The elimination half-life is the time it takes for half of the drug to be removed from the body. Regulatory documents report this time to be approximately 7 to 20 hours in adults with normal kidney function. It is noted that this time can be longer in patients with existing kidney issues.

Q: Does Flecoxin affect mood or cause anxiety?

Official labeling lists nervous system issues as uncommon adverse reactions, which include symptoms such as tremor and headache. Anxiety or changes in mood are generally not classified among the more commonly reported side effects of this medication.

Q: What happens if I miss a single dose of Flecoxin?

Official patient information often contains instructions for managing a missed dose. These guidelines usually describe when to take a remembered dose (if not close to the next scheduled time) or when it is appropriate to skip the missed dose entirely.

Q: Does taking Flecoxin affect a person's ability to drive or operate machinery?

Official product information includes warnings that the ability to drive or operate complex machinery may be impaired. This is due to the very common adverse effects of dizziness and visual disturbances that can occur, particularly when first starting treatment or after a dose adjustment.

Q: Are there any known issues with undergoing surgery while taking Flecoxin?

Regulatory documents emphasize the importance of monitoring during surgical procedures. Surgery can alter the balance of fluids and electrolytes in the body, which may affect how antiarrhythmic drugs like Flecoxin work. Continued cardiac monitoring is generally highlighted as necessary during and after this period.

Q: What happens if I stop taking Flecoxin suddenly?

Official warnings for medications used to manage heart rhythm state that abrupt discontinuation is not recommended. The regulatory information indicates that changes to therapy are typically managed under the direct supervision of a healthcare professional.

Q: Is Flecoxin a habit-forming drug?

Official regulatory labeling does not classify Flecoxin as a controlled substance. The product information does not include warnings regarding the risk of dependence or other habit-forming properties.

Q: Is it acceptable to cut or split Flecoxin tablets?

Instructions for the oral tablet form typically specify whether the tablet is scored (designed to be split) or if it must be swallowed whole. Splitting a tablet that is not designed to be split may alter the amount of medication absorbed, and for that reason, adherence to the administration instructions found in the product label is specified.

Q: What should be reported to a healthcare provider if noticed after starting Flecoxin?

Official warnings and precautions sections highlight specific serious or persistent adverse effects that regulatory documents identify as warranting the attention of a healthcare provider. Examples include the development of new or worsened cardiac rhythm disturbances, or visual changes that persist and do not resolve quickly.

How should Flecoxin be stored and disposed of?

How to Store and Dispose of Flecainide Acetate

Flecainide Acetate tablets must be stored according to official regulatory labeling to ensure product quality.

Storage Requirements

  • Temperature: Store at controlled room temperature, typically 15 C to 30 C.
  • Protection: The medicine must be kept away from freezing, excessive heat, moisture, and direct light.
  • Container: Store the medicine in its original, closed container.
  • Child Safety: It is mandatory to keep the tablets out of the sight and reach of children.
  • Expiry: The medicine must not be used after the printed expiry date.

Disposal Requirements

Disposal must not be done via household waste or wastewater.

Patients must consult a pharmacist to properly discard any unused or expired medication in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flecoxin found in:

A-Z Index: